VacZine Analytics  
ExpertREACT - PREMIUM

GSK's Synflorix: closer to a different market place?

Published 28th January 2009

Recently the EU Committee For Medicinal Products for Human Use (CHMP) adopted a positive opinion to recommend a marketing authorisation for GSK's new pneumococcal vaccine, Synflorix. The vaccine will compete in a fiercely competitive market dominated by Wyeth (PCV-7). With the recent Pfizer news, GSK are no doubt hoping the acquisition may affect an optimum PCV-13 launch. They also have longer-terms plans for pneumococcal vaccines.

PAGES: 2

PREMIUMThis article is available only to VacZine Analytics clients or can be purchased for delivery.

CAT No: CONTENTS: PRICE*: PURCHASE:
VAER090128 Click here>> USD $14.99 GBP 9.99
*Prices quotes are global use and distribution. For UK orders VAT will be added at 15.0%.

Return to main list>> Questions about this article?






© 2009 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains